|
|
| Description: |
| Patients: This Phase II study involved 15 patients with mesothelioma.
Treatment: The treatment consisted of the administration of the drug, doxorubicin (doxil). Toxicity: Toxicities included neutrophils (grade 3 and 4), skin (grade 1 and 2), mucositis (grade 1 and 2), nausea (grade 1), and fatigue (grade 1). Results: One patient had a partial response. Overall survival was not discussed. |